Other content in this Stream
From enabling the manufacturing of biopharmaceuticals to developing its own drug pipeline.
Prometic closes its extension of debt maturities to 2024
• Maturity Dates of the Line of Credit and Long-Term (OID) Loans extended to September 2024 • One of a number of measures underway to extend cash runway • Significant reduction in R&D costs of up ...
Prometic to report its third quarter 2018 financial results and hold conference call / webcast
LAVAL, QUEBEC, CANADA – November 12, 2018 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (“Prometic”) announced today that it will report its financial results for the third quarter ended Sep
Prometic announces extension of debt maturities to 2024
Annual Information Form 2017
Prometic Annual Information Form 2017
Quarterly Report Q2 2018
Quarterly Report Q1 2018
Prometic reports its 2018 first quarter highlights and financial results
Corporate Governance and Nominating Committee Charter 2017
Board of Directors Charter 2017
Audit, Risk and Finance Committee Charter 2017
Chairman Mandate 2018
Virtual Tour of Prometic Life Science's Manufacturing Process
Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency
At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).
Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment